<DOC>
	<DOCNO>NCT00256126</DOCNO>
	<brief_summary>The study aim identify predictive marker one month Saizen therapy Growth Hormone Deficiency ( GHD ) Turner Syndrome child . The study recruit approximately 360 child several country worldwide . The study last first one month daily growth hormone treatment . There three clinic visit month study . There initial visit , visit growth hormone treatment start finally visit fourth week treatment . The study require two additional blood test regular Saizen treatment follow-up . One sample take growth hormone injection start one additional blood sample take fourth week treatment .</brief_summary>
	<brief_title>Predictive Markers GHD TS Children Treated With SAIZEN®</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<criteria>One follow diagnosis candidacy SAIZEN® therapy : A ) GHD : document preestablished diagnosis GHD GH peak response &lt; 10 μg/L 2 GH stimulation test , without prim oestradiol . B ) Turner syndrome : document preestablished diagnosis karyotype . Prepubertal status accord Tanner Preestablished history normal thyroid function adequate substitution least 3 month . Weight stature within population specific normal range ( &gt; 5th &lt; 95th percentile ) gender Willingness ability comply protocol duration study . Parent 's guardian 's write informed consent , give study relate procedure part subject 's normal medical care , understand subject parent/guardian may withdraw consent time without prejudice future medical care . If child old enough read write , separate assent form give . Acquired GHD due central nervous system tumour , trauma , infection , infiltration ( documented imaging ) , history irradiation cranial surgery Previous treatment GH , GHRH , anabolic steroid treatment affect growth . Previous treatment corticosteroid , except case topical inhale corticosteroid administration atopic disease . Corticosteroids hormonal substitution also allow condition treatment regimen stable least 3 month . Severe associated pathology affect growth malnutrition , malabsorption , bone dysplasia . Chronic severe kidney disease . Chronic severe liver disease . Chronic infectious disease . Acute severe illness previous 6 month . Significant concomitant illness would interfere participation assessment study . Active malignancy ( except nonmelanomatous skin malignancy undergo surgical excision and/or biopsy , diagnosis treatment resolution ) History active Idiopathic intracranial hypertension ( benign intracranial hypertension pseudotumor cerebri ) . Diabetes Mellitus type I &amp; II . Any autoimmune disease . Previous screen failure study . Use investigational drug participation another clinical study within last three month .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>